08:15:39 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Beskrivning

LandSverige
ListaLarge Cap Stockholm
SektorHälsovård
IndustriMedicinteknik
Elekta är verksamma inom medicinteknik. Bolaget är idag specialiserade inom utvecklingen av kliniska lösningar för behandling av cancer och diverse hjärnsjukdomar. Elektas behandlingssystem och planeringsmjukvara för strålterapi och strålkirurgi samt övriga mjukvarusystem används inom sjukhusindustrin för att identifiera och analysera olika hälsotillstånd. Verksamhet innehas på global nivå, med huvudkontor i Stockholm.

Kalender

2020-05-29 Bokslutskommuniké 2020
2020-02-21 Halvårsutdelning EKTA B 0.90 SEK
2020-02-20 Kvartalsrapport 2020-Q3
2019-11-28 Kvartalsrapport 2020-Q2
2019-11-22 Kvartalsrapport 2020-Q2
2019-08-23 Halvårsutdelning EKTA B 0.90 SEK
2019-08-22 Kvartalsrapport 2020-Q1
2019-08-22 Årsstämma 2019
2019-05-29 Bokslutskommuniké 2019
2019-03-01 Halvårsutdelning EKTA B 0.70 SEK
2019-02-22 Kvartalsrapport 2019-Q3
2018-11-29 Kvartalsrapport 2019-Q2
2018-08-31 Halvårsutdelning EKTA B 0.70 SEK
2018-08-30 Årsstämma 2018
2018-08-30 Kvartalsrapport 2019-Q1
2018-06-01 Bokslutskommuniké 2018
2018-03-02 Kvartalsrapport 2018-Q3
2018-02-22 Halvårsutdelning EKTA B 0.50 SEK
2017-11-30 Kvartalsrapport 2018-Q2
2017-08-24 Halvårsutdelning EKTA B 0.50 SEK
2017-08-23 Kvartalsrapport 2018-Q1
2017-08-23 Årsstämma 2017
2017-06-01 Bokslutskommuniké 2017
2017-03-03 Halvårsutdelning EKTA B 0.25 SEK
2017-03-01 Kvartalsrapport 2017-Q3
2016-12-01 Kvartalsrapport 2017-Q2
2016-09-26 Kapitalmarknadsdag 2016
2016-09-02 Halvårsutdelning EKTA B 0.25 SEK
2016-09-01 Årsstämma 2016
2016-09-01 Kvartalsrapport 2017-Q1
2016-06-01 Bokslutskommuniké 2016
2016-03-02 Kvartalsrapport 2016-Q3
2015-12-03 Kvartalsrapport 2016-Q2
2015-09-02 Ordinarie utdelning EKTA B 0.50 SEK
2015-09-01 Kvartalsrapport 2016-Q1
2015-09-01 Årsstämma 2015
2015-06-02 Bokslutskommuniké 2015
2015-03-04 Kvartalsrapport 2015-Q3
2014-11-27 Kvartalsrapport 2015-Q2
2014-11-27 Analytiker möte 2014
2014-09-15 Kapitalmarknadsdag 2014
2014-08-29 Ordinarie utdelning EKTA B 1.50 SEK
2014-08-29 Bonusutdelning EKTA B 0.50 SEK
2014-08-28 Kvartalsrapport 2015-Q1
2014-08-28 Årsstämma 2014
2014-08-28 Analytiker möte 2015
2014-05-28 Bokslutskommuniké 2014
2014-05-28 Analytiker möte 2014
2014-02-27 Kvartalsrapport 2014-Q3
2013-12-04 Kvartalsrapport 2014-Q2
2013-09-23 Kapitalmarknadsdag 2013
2013-09-04 Bonusutdelning EKTA B 0.50 SEK
2013-09-04 Ordinarie utdelning EKTA B 1.50 SEK
2013-09-03 Kvartalsrapport 2014-Q1
2013-09-03 Årsstämma 2013
2013-06-05 Analytiker möte 2013
2013-06-05 Bokslutskommuniké 2013
2013-03-05 Kvartalsrapport 2013-Q3
2013-03-05 Extra Bolagsstämma 2013
2012-12-04 Kvartalsrapport 2013-Q2
2012-10-29 Kapitalmarknadsdag 2012
2012-09-12 Split EKTA B 1:4
2012-09-05 Ordinarie utdelning EKTA B 5.00 SEK
2012-09-03 Årsstämma 2012
2012-09-03 Kvartalsrapport 2013-Q1
2012-06-05 Bokslutskommuniké 2012
2012-06-05 Analytiker möte 2012
2012-04-02 Extra Bolagsstämma 2012
2012-03-05 Kvartalsrapport 2012-Q3
2011-12-02 Kvartalsrapport 2012-Q2
2011-09-14 Ordinarie utdelning EKTA B 4.00 SEK
2011-09-13 Årsstämma 2011
2011-09-13 Kvartalsrapport 2012-Q1
2011-06-09 Bokslutskommuniké 2011
2011-03-08 Kvartalsrapport 2011-Q3
2010-12-07 Kvartalsrapport 2011-Q2
2010-09-22 Ordinarie utdelning EKTA B 3.00 SEK
2010-09-21 Kvartalsrapport 2011-Q1
2010-06-09 Bokslutskommuniké 2010
2010-03-10 Kvartalsrapport 2009-Q3
2009-12-10 Kvartalsrapport 2009-Q2
2009-09-16 Ordinarie utdelning EKTA B 2.00 SEK
2009-09-15 Kvartalsrapport 2009-Q1
2009-09-15 Årsstämma
2008-09-19 Ordinarie utdelning EKTA B 1.75 SEK
2007-09-26 Ordinarie utdelning EKTA B 1.00 SEK
2006-09-21 Ordinarie utdelning EKTA B 1.00 SEK
2005-10-17 Split EKTA B 1:3
2005-09-22 Ordinarie utdelning EKTA B 6.60 SEK
2004-09-22 Ordinarie utdelning EKTA B 0.00 SEK
2003-09-23 Ordinarie utdelning EKTA B 0.00 SEK
2002-10-01 Ordinarie utdelning EKTA B 0.00 SEK
2001-09-28 Ordinarie utdelning EKTA B 0.00 SEK
2000-10-02 Ordinarie utdelning EKTA B 0.00 SEK
1999-09-23 Ordinarie utdelning EKTA B 0.00 SEK
2019-07-30 12:00:00

Australian-headquartered cancer care provider to make state-of-the-art precision radiation medicine available globally

SYDNEY, Australia, July 30, 2019 - Elekta (EKTA-B.ST) announces that it has received one of its largest orders to date for nine Elekta Unity systems. Australian-headquartered GenesisCare, one of the largest providers of radiation therapy in the world, will install the units in Australia, Asia Pacific and Europe, improving global access to Elekta's next generation radiotherapy platform. This order brings the total number of Unity systems ordered by GenesisCare to 10, including the purchase of a Unity system announced in 2018 (https://www.elekta.com/meta/press-all.html?id=8EE789E2E2229703).

Elekta Unity combines a state-of-the-art 1.5T MRI scanner and a best-in-class 7MV linear accelerator, giving it the ability to reshape the radiation dose based on daily changes in shape, size and position of tumor and surrounding healthy anatomy. This groundbreaking technology enables accurate dose delivery with real-time visualization of the tumor so that doctors can better target cancers and minimize risk to surrounding tissue.

Dan Collins, CEO at GenesisCare, said: "This innovative technology represents a new era in radiotherapy. It will provide new hope for patients with types of cancer that have been challenging to treat, including pancreatic cancer, liver cancer, head and neck cancers, and other soft tissue tumor groups including prostate cancer. Our order for nine further Elekta Unity systems will increase access to this cutting-edge technology, as we focus on improving the life outcomes of people with cancer around the world."

The agreement also extends the strategic partnership between GenesisCare and Elekta to include a program to advance the ongoing clinical development of adaptive therapy based on real-world evidence. Using GenesisCare's global network, built on a backbone of Elekta's oncology information systems, both organizations will work together to create standardized data repositories that advance adaptive therapy technologies and create a platform to assess the clinical value of radiotherapy.

Richard Hausmann, CEO at Elekta, said: "We share GenesisCare's focus on patients. With this order, cancer patients - and those who treat them - will have greater access to MR-guided adaptive therapy, the most precise form of radiation treatment. In addition, to help realize our common long-term vision for radiotherapy, we are establishing an innovative partnership to generate and leverage real-world evidence that speaks to the needs of every stakeholder: device manufacturers, policy makers and, most importantly, patients and their advocates."

The total value of the agreement is USD 58 million and will be booked in the first quarter of Elekta's 2019/20 fiscal year. The first deliveries are scheduled for mid-2020.

To learn more, visit elekta.com/Unity (http://www.elekta.com/unity).

Elekta Unity is CE marked and 510(k) cleared. It is not commercially available in all markets.  

# # #

For further information, please contact:
Oskar Bosson, Global EVP Corporate Communications and Public Affairs
Tel: +46 70 410 7180, e-mail: Oskar.Bosson@elekta.com  
Time zone: CET: Central European Time

Cecilia Ketels, Head of Investor Relations
Tel: +46 76 611 76 25, e-mail: cecilia.ketels@elekta.com
Time zone: CET: Central European Time

This is information that Elekta AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication at 12:00 CET on July 30, 2019. (REGMAR) 

About Elekta
For almost five decades, Elekta has been a leader in precision radiation medicine. Our nearly 4,000 employees worldwide are committed to ensuring everyone in the world with cancer has access to - and benefits from - more precise, personalized radiotherapy treatments. Headquartered in Stockholm, Sweden, Elekta is listed on NASDAQ Stockholm Exchange. Visit elekta.com (http://www.elekta.com) or follow @Elektaon Twitter.